Centre for Transplant and Renal Research
Led by Professor Philip O'Connell and Professor Natasha Rogers, there are two broad themes within the Centre: transplantation and renal research. A major focus of the Transplant stream has been the development of cell-based therapies for patients with type 1 diabetes. In this work CTRR is developing alternate beta cells and for transplantation and studies ways to prevent rejection and how to boost long term outcomes. The Kidney injury group has a focus on the molecular pathways involves in kidney resuscitation prior to transplantation and the Transplant Genomics group identifies biomarkers that predict long and short term graft outcomes. The second major focus of CTRR is renal research. This research tries to understand the underlying processes of chronic kidney disease and to develop ways of slowing disease progression. One focus of this research is cystic renal disease, with preclinical and clinical research projects aimed at preventing kidney failure due to autosomal dominant polycystic kidney disease.
Our research focus
- Development of cell-based therapies for patients with type 1 diabetes
- Molecular pathways involves in kidney resuscitation prior to transplantation
- Underlying processes of chronic kidney disease and to develop ways of slowing disease progression
- Cystic renal disease
Research groups within this centre
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
Recent achievements
The Centre has strong links with Westmead Hospital with 4 clinicians/researchers leading research groups in CTRR.
Proven translational capacity of research e.g.
- Australian first clinical trial for normothermic kidney perfusions
- Translation of islet transplantation to the clinic
- Improved outcome for polycystic kidney disease
- Improving organs for transplantation
- Identify predictive biomarkers as tools for precision medicine transplant outcomes
- Participation in major clinical trials e.g. the Tempo 3:4 and REPRISE Trials which led to approval of tolvaptan by PBS.
Clinical issues readily inform research questions such as the introduction of genomics and personalised medicine tools for predicting transplant outcomes.
Extensive biomarkers of human tissue and concurrent data for islet transplantation and Kidney/Kidney-pancreas recipients.
Broad range of animal models for:
- Solid organ transplantation
- Islet transplantation
- Acute and chronic kidney injury models
- Machine profusion
CTRR has invitro technical strengths in immunophenotyping and IMC.
Recent publications
The impact of cytoplasmic ubiquitin ligase TNFAIP3 gene variation on transcription factor NF-B activation in acute kidney injury.
Tolerogenic dendritic cells protect against acute kidney injury.
Multiscale genetic architecture of donor-recipient differences reveals intronic LIMS1 mismatches associated with kidney transplant survival.
Deep-learning Based Pathological Assessment of Frozen Procurement Kidney Biopsies Predicts Graft Loss and Guides Organ Utilization: A Large-scale Retrospective Study.
Novel metabolic role for CD47 in pancreatic -cell insulin secretion and islet transplant outcomes.
Human HLA-DR+CD27+ regulatory T cells show enhanced antigen-specific suppression both in vitro and in vivo
Prospective observational study to validate a next generation sequencing blood RNA signature to predict early kidney transplant rejection.
. Intragraft memory-like CD127highCD4+Foxp3+ regulatory T cells maintain tolerance..
Decoding the hallmarks of allograft dysfunction with a comprehensive pan-organ transcriptomic atlas.
LILRB3 genetic variation is associated with kidney transplant failure in African American recipients.
Thrombospondin-1 Drives Cardiac Remodeling in Chronic Kidney Disease.
Regulating islet stress responses through CD47 activation.
Gasdermin D mutation protects against renal ischemia reperfusion injury. Physiol Reports.
Targeting inflammation with chimeric antigen receptor macrophages using a signal switch.
SUPPORT US
With your support, we can continue to explore groundbreaking research and improved health outcomes for people everywhere.
